ATE336999T1 - Verfahren zur inhibition einer neoplastischen krankheit in saeugetieren - Google Patents

Verfahren zur inhibition einer neoplastischen krankheit in saeugetieren

Info

Publication number
ATE336999T1
ATE336999T1 AT96922478T AT96922478T ATE336999T1 AT E336999 T1 ATE336999 T1 AT E336999T1 AT 96922478 T AT96922478 T AT 96922478T AT 96922478 T AT96922478 T AT 96922478T AT E336999 T1 ATE336999 T1 AT E336999T1
Authority
AT
Austria
Prior art keywords
mammal
mammals
prolactin profile
neoplastic disease
inhibiting
Prior art date
Application number
AT96922478T
Other languages
English (en)
Inventor
Albert H Meier
Anthony H Cincotta
Original Assignee
Pliva D D
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/475,296 external-priority patent/US5792748A/en
Application filed by Pliva D D, Univ Louisiana State filed Critical Pliva D D
Application granted granted Critical
Publication of ATE336999T1 publication Critical patent/ATE336999T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT96922478T 1995-06-07 1996-06-05 Verfahren zur inhibition einer neoplastischen krankheit in saeugetieren ATE336999T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/475,296 US5792748A (en) 1995-06-07 1995-06-07 Method for inhibiting neoplastic disease in mammals
US08/656,103 US6071914A (en) 1995-06-07 1996-05-31 Method for inhibiting neoplastic disease in mammals

Publications (1)

Publication Number Publication Date
ATE336999T1 true ATE336999T1 (de) 2006-09-15

Family

ID=27044737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922478T ATE336999T1 (de) 1995-06-07 1996-06-05 Verfahren zur inhibition einer neoplastischen krankheit in saeugetieren

Country Status (7)

Country Link
EP (1) EP0833636B1 (de)
JP (2) JPH11507386A (de)
AT (1) ATE336999T1 (de)
CA (1) CA2219978C (de)
DE (1) DE69636474T2 (de)
ES (1) ES2274527T3 (de)
WO (1) WO1996040132A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3216870A1 (de) * 1982-05-03 1983-11-03 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische zubereitungen mit zytostatischer wirkung
HU193317B (en) * 1985-06-12 1987-09-28 Richter Gedeon Vegyeszet Process for producing 2-bromo-alpha-ergochristin
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
GB8829330D0 (en) * 1988-12-16 1989-02-01 Sandoz Ltd Improvements in or relating to organic compounds
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharma 1991 Melatonin enthaltende Arzneimittel
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals

Also Published As

Publication number Publication date
JPH11507386A (ja) 1999-06-29
WO1996040132A1 (en) 1996-12-19
EP0833636A4 (de) 1998-11-25
EP0833636A1 (de) 1998-04-08
CA2219978C (en) 2011-02-01
EP0833636B1 (de) 2006-08-23
JP2007302702A (ja) 2007-11-22
ES2274527T3 (es) 2007-05-16
CA2219978A1 (en) 1996-12-19
DE69636474T2 (de) 2007-06-14
DE69636474D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
ATE224191T1 (de) Verfahren zur bekämpfung neoplastischer krankheiten bei säugetieren
DE69925609D1 (de) Verfahren zur textilbehandlung
DE69713022D1 (de) Verfahren zur Herstellung von Unterkleidung
DE69434672D1 (de) Verfahren zur behandlung von hühnereiern
DE69114869D1 (de) Verfahren zur Bestimmung des Profils von Reifen.
DE69838789D1 (de) Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DK0938326T3 (da) Syntetiske phosphopeptider til behandling af knoglesygdomme
DE69605837D1 (de) Verfahren zur Risswachstumsverringerung
ATE215936T1 (de) Verfahren zur herstellung von reinem melamin
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
MX9401294A (es) Derivados de azolona sustituida
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69129908D1 (de) Verfahren zur helligkeitsverbesserung
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69607559T2 (de) Verfahren zur Behandlung von Phenolteer
ATE336999T1 (de) Verfahren zur inhibition einer neoplastischen krankheit in saeugetieren
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69618481D1 (de) Verfahren zur herstellung von halogenkohlenwasserstoffen
DE69112112D1 (de) Methoden zur Kompensation optischer Relaxationstransienten.
DE69622956T2 (de) Methode zur Regelung der Bestandteile eines Phosphatbades
DE69905263T2 (de) Verfahren zur dekorativen behandlung von oberflächen
DE69626171T2 (de) Verfahren zur Herstellung von 1-substituierten Tetrahydrochinazolindionen
BR9612549A (pt) Método para tratamento de agressão excessiva
DE59505180D1 (de) Verfahren zur Herstellung von Chinazolin-2,4-dionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833636

Country of ref document: EP

REN Ceased due to non-payment of the annual fee